Skip to main content Skip to search Skip to main navigation

VDI: Update of Cleanroom Standards 2083 4.1 and 2083 4.2

The Association of German Engineers (VDI) has updated and published for comment its cleanroom standards, VDI 2083 Part 4.1 and Part 4.2. Part 4.1 covers the planning, construction, and initial commissioning of cleanrooms, and Part 4.2 covers the energy efficiency of cleanrooms.

2083 Part 4.1 – Planning, construction, and start-up of cleanrooms:

The currently valid version dates from 2006 and had to be adapted to the state of the art. The current draft provides a structured approach for planning, constructing, and commissioning cleanrooms – covering both new builds and modernisations. Annexes include checklists to support systematic project execution.

At 70 pages, it is significantly longer than the previous 48-page version.

2083 Part 4.2 – Energy efficiency:

The previous version of Part 4.2 was published in 2011. This update shortens the document from 59 pages to 47. The draft focuses on the energy-saving potential of cleanrooms. It offers recommendations for reducing energy consumption in new and existing clean areas, with a particular focus on ventilation and air conditioning technology. Defining energy-related limit values is central to efficient cleanroom design.

Comments on both standards can be submitted until December 31, 2025.


Source:

VDI: Standards


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

How is a QRM process initiated?

How is a QRM process initiated?

You can view the answer here:
Read more
FDA: Updated Pre-RFD Guidance for Combination Products

FDA: Updated Pre-RFD Guidance for Combination Products

The U.S. FDA has released an updated final guidance on preparing a Pre-Request for Designation (Pre-RFD), replacing the previous 2018 version. The revised document provides new recommendations for interacting with the Office of Combination Products (OCP) and clarifies expectations for Pre-RFD submissions.
Read more
EDQM: 9 Virtual Training Modules on Ph. Eur. and CEPs

EDQM: 9 Virtual Training Modules on Ph. Eur. and CEPs

The EDQM has introduced a modular training programme covering chemically defined active substances and medicinal products. It will take place between 1 and 12 December 2025.
Read more
 Data Integrity and Data Governance

Data Integrity and Data Governance

Data integrity is a key element in the pharmaceutical quality assurance system which has gained importance in recent years, especially from the viewpoint of the authorities. In GxP-regulated companies, managers are responsible for identifying and minimising risks to data integrity (“data governance”).

Read more
EMA Clarifies “Novel or Complex Manufacturing Process” Definition

EMA Clarifies “Novel or Complex Manufacturing Process” Definition

In its Quality of Medicines Q&A – Part 1, the EMA has clarified how “novel or complex manufacturing processes” should be interpreted for variation categories Q.II.b.1 (new/replacement finished product manufacturing site) and Q.II.b.4 (change in batch size).
Read more
EU: Environment Committee Comments on EU Regulation Regarding Critical Medicines

EU: Environment Committee Comments on EU Regulation Regarding Critical Medicines

The Environment Committee of the European Parliament has issued its opinion on the proposed EU Regulation to strengthen the availability of critical medicines. Key recommendations include fast-track permitting, simplified environmental assessments, and support for strategic manufacturing projects to boost EU production capacity.
Read more
Previous
Next